Published in J Clin Oncol on September 04, 2007
Multiple myeloma. Blood (2008) 5.88
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol (2010) 3.09
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol (2009) 2.48
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma (2009) 1.63
IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29
Treatment of newly diagnosed myeloma. Leukemia (2008) 1.27
Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents. Haematologica (2010) 1.14
Association of response endpoints with survival outcomes in multiple myeloma. Leukemia (2013) 1.08
Multiple myeloma. Curr Probl Cancer (2009) 1.04
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica (2012) 1.00
Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol (2012) 1.00
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol (2010) 0.99
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma (2012) 0.97
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma. Leukemia (2013) 0.97
Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs (2009) 0.96
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica (2013) 0.94
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant (2010) 0.90
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid (2010) 0.89
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica (2010) 0.88
Compromising the unfolded protein response induces autophagy-mediated cell death in multiple myeloma cells. PLoS One (2011) 0.88
A highly sensitive fluorimetric method for determination of lenalidomide in its bulk form and capsules via derivatization with fluorescamine. Chem Cent J (2012) 0.88
Changing paradigms in the treatment of multiple myeloma. Haematologica (2009) 0.87
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk (2013) 0.84
Thalidomide and its analogues in the treatment of Multiple Myeloma. Exp Hematol Oncol (2012) 0.83
Multiple myeloma. Clin Cases Miner Bone Metab (2012) 0.81
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. Biomed Res Int (2015) 0.81
How best to use new therapies in multiple myeloma. Blood Rev (2010) 0.81
Current therapeutic strategies for multiple myeloma. Int J Clin Oncol (2015) 0.81
Multiple Myeloma, Version 2.2016. J Natl Compr Canc Netw (2015) 0.81
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. Blood (2015) 0.80
Multiple myeloma: an update. Oman Med J (2013) 0.79
New Treatment Approaches for Older Adults with Multiple Myeloma. J Geriatr Oncol (2012) 0.79
Multiple myeloma: biology, standard therapy, and transplant therapy. Biol Blood Marrow Transplant (2009) 0.78
Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus. Adv Hematol (2012) 0.78
Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates. Cancer J (2009) 0.77
Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol (2010) 0.76
Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma. Eur J Clin Pharmacol (2011) 0.76
Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion. Ecancermedicalscience (2010) 0.75
Synthesis of hapten and preparation of specific polyclonal antibody with high affinity for lenalidomide, the potent drug for treatment of multiple myeloma. Chem Cent J (2012) 0.75
Evolving role of high dose stem cell therapy in multiple myeloma. Indian J Med Paediatr Oncol (2011) 0.75
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. J Korean Med Sci (2013) 0.75
Is there a role for 'modified VAD' in the treatment of multiple myeloma? Ecancermedicalscience (2009) 0.75
Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. Leuk Suppl (2013) 0.75
Novel treatment paradigm for elderly patients with multiple myeloma. Am J Blood Res (2011) 0.75
Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine. Chem Cent J (2013) 0.75
Novel agents have a significant impact on survival of patients with multiple myeloma. Wien Klin Wochenschr (2015) 0.75
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med (2005) 8.80
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med (2007) 8.77
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med (2006) 8.16
BRAF mutations in hairy-cell leukemia. N Engl J Med (2011) 7.05
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med (2005) 4.96
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 3.99
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood (2007) 3.64
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol (2013) 3.58
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med (2008) 3.24
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood (2006) 2.97
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood (2010) 2.84
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood (2007) 2.80
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol (2008) 2.80
Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood (2011) 2.71
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood (2008) 2.68
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leuk Lymphoma (2014) 2.66
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol (2009) 2.59
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood (2012) 2.58
Maternal complications and procedures in pregnancy and at birth and wheezing phenotypes in children. Am J Respir Crit Care Med (2006) 2.56
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 2.54
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood (2014) 2.53
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood (2011) 2.44
Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leuk Lymphoma (2007) 2.41
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood (2011) 2.37
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol (2004) 2.36
Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med (2014) 2.33
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol (2009) 2.32
Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol (2008) 2.30
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol (2009) 2.27
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol (2010) 2.25
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol (2009) 2.19
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol (2009) 2.09